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Considerations about TASC II:
Is it a Suitable Document for Specialists?The Trans-Atlantic Inter-Society Consensus Document
on Management of Peripheral Arterial Disease
(TASC)1e3 was a milestone for angiology and vascular
surgery impacting on the indications and treatment of
vascular diseases. I think that many surgeons, angio-
logists and interventional radiologists were waiting
for its revision, as stated in the last sentence of the first
chapter ‘‘the participating societies therefore commit them-
selves to continuing the update process’’.
It’s true that in the following years many national
Vascular Societies wrote their guidelines, based on
the new experiences, expanded to all fields of vascular
pathology and applicable to the local availability.
Nevertheless, the update of so detailed document
was an expected event.
The Authors declare the new goals of TASC II,4,5
that is addressed also to physicians in primary health
care, saying that they wont ‘‘to focus on key aspects of
diagnosis and management, and to update the information
based on new publications and the newer guidelines, but
not to add an extensive list of references’’.
The second edition of the Consensus is intention-
ally abbreviated and with less references based on
the concept that: ‘‘Unreferenced statements are, therefore,
to be found, provided they are recognized as common prac-
tice by the authors, with existing evidence’’.
So I could conclude that TASC II is a disappointing
document for specialist like me that imagined the con-
sensus as a document produced to analyze in particu-
lar the argument with low evidence, and to state in
few sentences the evidence based knowledge.
Moreover the document is disappointing for the
many mistakes and inaccuracies.
Analyzing the chapter on revascularization, the re-
ported citations are mainly review and meta-analysis
of old publication in which surgeons used graft
deeply modified. For example, the Table F7a, that
summarizes the 5-year patency following femoral
popliteal bypass, is taken from a paper of 1994,6 more-
over the reported citation is wrong, being referred to
a meta-analysis of aortic surgery.71078–5884/000411+ 04 $32.00/0  2007 Published by Elsevier Ltd oThe figures of this table, as in other papers reported
in literature, show better results of vein bypass, in
particular in chronic critical limb ischemia (CLI),
and the equivalence of vein and expanded polytetra-
fluoroethylene (PTFE) in above the knee position in
patients with claudication. In the section ‘‘F3.3.2 Con-
duit’’ the authors declare that ‘‘Vein has better long-
term patency than prosthetic in the infra inguinal region
(Table F7). Over the short term, PTFE has delivered near
equivalent results in the above-knee position (Fig. F6)’’.
This sentence is clearly in contrast with the figures
reported in the Table F7b.
Moreover, in this table the authors cited 2 paper:
the first is a prospective randomized multicentric trial
of Green et al.8 that compares PTFE with Dacron He-
mashield (and not with the vein) implanted between
1991 and 1996 in the above the knee position. This
paper reports unexpected results of polyester graft
(5 year secondary patency of 68% for both conduits),
that indeed now is rarely used in femoro-distal
revascularization.
The other paper cited in Table F7b is a report of
Klinkert,9 that deal with femorotibial bypass grafting
and not with A-K femoropopliteal graft. Very proba-
bly the authors would refer to another paper pub-
lished by Klinkert10 in the same year but in another
journal. This paper reports a 5 year primary patency
of 75.6% in the vein group and of 51.9% for PTFE
( p¼ 0.035); secondary patency are 79.7% and 57.2%
respectively ( p¼ 0.036), without difference of limb
salvage. This is one of the randomized paper with
the worse results of PTFE conduit in the above the
knee position.
Analyzing these data one can conclude that the
numbers reported in the Table F7b does not corre-
spond to the cited articles.
Other studies support the equivalences of vein and
PTFE for above the knee revascularisations, in particu-
lar for the secondary patency, either for claudication
and for CLI, but a significantly difference for primary
patency; one of these is a meta-analysis11 thatn behalf of European Society for Vascular Surgery.
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regarding more than 6000 procedures. Even this meta-
analysis (not reported very probably because pub-
lished contemporarily with TASC II), show the lower
early patency of PTFE in AK position and the greater
need of redo treatment to reach an secondary patency
equivalent to those reached with the vein.
Very probably the most interesting prospective ran-
domized study has been reported by Ballotta et al.12
whose 51 patients (102 limbs) underwent between
1994 and 1997 to a vein bypass in one limb and to
a PTFE bypass in the other. This study avoid some im-
portant bias: the biologic differences between patients,
all patients had bilateral disabling claudication and all
were operated by the same group. The primary assis-
ted patency at 1, 3 and 5 year follow-up were: 100%,
98%, and 94% for vein grafts, and 96%, 84%, and
84% for PTFE grafts respectively; the differences
were not statistically significant (p¼ .09). Even this
paper was not reported in TASC II.
Many other prospective randomized controlled
trial13 such as retrospective review of series14
showed no statistical difference between secondary
or assisted patency between vein and PTFE in AK
revascularization, even if the primary patency is
significantly better for vein graft.
The paper of Allen15 did not show any differences
even in BK position (5 year primary patency of 55%
with PTFE and 60.3% with vein bypass ( p¼ 0.88),
and secondary patency of 79.2, 73.3 and 74.4% respec-
tively ( p¼ 0.84).
Analyzing these and many others data, the equiva-
lence between vein and PTFE could be acceptable;
but, at the same time, I think the justification of
many surgeons (me included) to spare the saphenous
vein for BK or coronary bypass should be discussed
by the consensus’ authors.
Pereira et al.11 did not analyze limb salvage, they re-
marked the lower use of saphenous vein in the AK
Table F7a. 5-year patency following femoral popliteal bypass191
Claudication CLI
Vein 80 66
Above-knee PTFE 75 47
Below-knee PTFE 65 65
CLI - critical limb ischemia; PTFE - polytetrafluoroethylene graft.
Table F7b. Randomized trials of types of conduits206e209
Above-knee femoral popliteal bypass 5-year patency
Vein 74e76%
PTFE 39e52%
PTFE - polytetrafluoroethylene graft.Eur J Vasc Endovasc Surg Vol 34, October 2007position (580 vs 1713 in claudication and 703 vs 2431
in CLI), and concluded that vein sparing is not justi-
fied because of an amputation rate double using
PTFE (citing a paper of 198816), because the need for
redo treatment is higher, and moreover because the
rate of use of saved vein in a late bypass has been con-
sistently low. Similarly Berglund17 analyzing retro-
spectively the results of Swedvasc, concluded that
PTFE cannot be recommended in claudicants, since
occlusion occurs often and frequently leads to CLI.
If a surgeon looks at these 2 papers (one of which is
a Class I publication), should say that in AK position
the 2 graft are non equivalent.
The authors of TASC II do not give recommenda-
tions on this controversial point but, citing a retrospec-
tive not randomized trial with some bias,18 they
remind that the occlusion of PTFE graft need a higher
number of redo operation (that it is true), with signif-
icantly worse limb salvage (81% with the vein and
56% with PTFE; p¼ 0.019); these results contrast
with other paper reported above.
Other two important points were not analyzed by
TASC II authors: the alternative conduits to PTFE
and the results of new generations of PTFE (thin wall,
ringed grafts, stretched grafts, carbon-impregnated
grafts, pre-cuffed grafts, heparin bonded grafts).
The authors of a Cochrane review19 in 1999, con-
cluded ‘‘there is no clear evidence which type of graft is
best for femoro-popliteal grafting. In terms of autologous
graft patency, in-situ and reversed vein grafts are equally
successful, while HUV performs better than PTFE. A distal
vein cuff may improve primary patency for below-knee
PTFE femoro-popliteal grafts’’.
More recently alternative grafts have been ana-
lyzed by Albers20 with a meta-analysis of studies
published from 1982 through 2003. This study
shows that the best limb salvage was achieved
with cryopreserved arteries, followed by cryo-
preserved veins, umbilical-cord veins, and cold-
storaged veins. Surprisingly a paper of Devine21
reports the results of the only prospective random-
ized trial on 209 femoropopliteal reconstruction
(179 AK and 30 BK), that show a significant better
patency of heparin-bonded Dacron (HBD) compared
with untreated PTFE. After 5 years the differences
were no more significant, but limb salvage was
better in HBD group ( p¼ 0.025).
As RCT on the new grafts are missing, the analysis
of series and registries should be useful to produce
the first observations, to define the limits of the
existing publications, and to find a consensus for
surgeons.
Similar considerations can be done about the new
endovascular devices as drug-eluting stents, nitinol
413Editorialstents, carbofilm-coated stents, reabsorbable stents,
and stent-grafts.
TASC II cite the meta-analysis of Muradin22 that
concludes ‘‘balloon dilation and stent implantation for
claudication and stenosis yield similar long-term patency
rates. For more severe femoropopliteal disease, the results
of stent implantation seem more favourable’’, and 3 stud-
ies of Cejna,23 Grimm e Vroegindeweij that reports
results of Palmaz stent, almost no more utilized for
femoro-popliteal lesions.
The cited randomized study24 tested a drug-
eluting stents against bare stents in femoro-popliteal
artery obstructive disease in claudicants. TASC II
emphasize the significantly larger in-stent mean
lumen diameter in the sirolimus-eluting stent group
(4.95 mm versus 4.31 mm in the uncoated stent
group; p¼ 0.047); the authors of the study conclude
more prudently: ’’Although there is a trend for greater
efficacy in the sirolimus-eluting stent group, there were
no statistically significant differences in any of the
variables’’.
Another argument I would emphasize is the en-
dovascular treatment of claudication. The authors
conclude, without grading their statement or writing
a recommendation: ‘‘Endovascular treatment of infrain-
guinal disease in patients with intermittent claudication
is an established treatment modality. The low morbidity
and mortality of endovascular techniques such as PTA
makes it to the preferred choice of treatment in limited
disease such as stenoses/occlusions up to 10 cm in
length.’’ This statement seems in contrast with the re-
sults published by cited authors25 that reports at
6 months, a restenosis rate of 24% in the stent group
and 43% in the angioplasty group (P¼ 0.05); and
a 12 months restenosis rates of 37 percent and 63
percent, respectively (P¼ 0.01), that conclude that
in the intermediate term, treatment of superficial-
femoral-artery disease by primary implantation of
a self-expanding nitinol stent yielded results that
were superior to those with the currently recommen-
ded approach of balloon angioplasty with optional
secondary stenting.
Moreover this statement seems in contrast even
with the flow-chart (Fig. C3) reported in the chapter
of claudication treatment, that take in consideration
the angiographic or radiological evaluation only in
patients with suspected proximal (aorto-iliac) lesions.
More prudent were the writer of the ACC/AHA
guidelines, version 2005,26 that in the chapter
‘‘2.6.2.4. Endovascular Treatment for Claudication’’
recommend: Endovascular procedures are indicated for
individuals with a vocational or lifestyle-limiting dis-
ability due to intermittent claudication when clinical
features suggest a reasonable likelihood of symptomaticimprovement with endovascular intervention and (a) there
has been an inadequate response to exercise or pharma-
cological therapy and/or (b) there is a very favorable
risk-benefit ratio (e.g., focal aortoiliac occlusive disease).
(Class I - Level of Evidence: A).
In the last 3 years, searching on Pubmed for ‘‘endo-
vascular treatment for claudications’’ with the limits
of ‘‘meta-analysis e RCT, Controlled Clinical Trial
and Multicenter Study’’ we can find only 9 paper,
very probably 6 of these were available before the
publication of TASC II, including the cited paper.25
None of these paper gives results useful to change
the ACC/AHA recommendation.
In the remaining 3 paper, the first27 concludes: ‘‘.re-
sults are inferior to those of conventional femoro-popliteal
synthetic bypass grafts. In order to become competitive to
conventional bypass surgery, further technical refinements
will be necessary.’’.
The aSpire Registry, including the treatment of SFA
stenosis in 55/166 enrolled patients, reports a13% pro-
cedural complications and a 1 year 74.2% secondary
patency obtained with 32 (19.3%) reinterventions, at
a mean follow-up of 13 months.28 The last paper deals
with benefits of a supervised exercise program after
lower limb bypass surgery.
These data do not support the endovascular treat-
ment of any type of claudication.
The last topic that should have been treated more
accurately by TASC II is the management of patients
at risk of ischemia, those with a claudication <100 m,
the so-called ‘‘chronic subclinical ischemia. In the
chapter D6-Prevention of Critical Limb Ischemia the au-
thors refer only to aggressive management of cardio-
vascular risk factors, but evidently they did not find
any useful data to suggest the revascularization of
patients in this phase, that seem more dangerous
than the mild or moderate claudication stage. In
other terms, in TASC II it is not clear which patients
should be scheduled for an invasive treatment.
It is evident that authors did not have enough mul-
tiple randomized clinical trials, meta-analyses, single
randomized trial or nonrandomized studies to give
strong recommendations, however they should reach
sufficient agreement on many items using the pub-
lished paper or state their limits. Moreover, the Scien-
tific Societies that endorsed the guidelines, well
knowing the lack of information that obliged to grade
C recommendations in the first edition of TASC should
have promoted or sponsored the necessary studies to
give an answer to many of the unresolved questions.
The mistakes, the inaccuracies and the lack of infor-
mation I report is only a part of which can be found
reading this document, that we hoped more accurate
after a so long period needed for its revision.Eur J Vasc Endovasc Surg Vol 34, October 2007
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